Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.

Bombardier Inc. (BBD.B-T) says its transportation divison has received an order from Lower Saxony’s regional public transport operator in Germany, Landesnahverkehrsgesellschaft Niedersachsen (LNVG), for 14 additional Bombardier Twindexx Vario double-deck coaches.

“A total of 12 intermediate cars and two control cars will be delivered,” the company stated, increasing LNVG’s fleet to 246 Twindexx Vario double-deck coaches in addition to the 37 Traxx locomotives already in service.

Story continues below advertisement

**

Neptune Wellness Solutions, Inc. (NEPT-Q; NEPT-T) announced an import and stocking distribution partnership with “one of the world’s leading consumer goods companies.”

Neptune said it expects to receive first shipments of products into its inventory by the end of October. “It should be noted that the distribution agreement does not require any minimum annual purchase commitments, acceptance of orders placed by Neptune are at the discretion of the global consumer product company. Accordingly, there is no certainty at this time that the full deal size will be realized,” the company stated.

**

Dye & Durham Ltd. (DND-T) says it lost $3.8-million in its fourth quarter compared with a profit of $1.7-million in the same quarter a year earlier.

The cloud-based software company says the loss amounted to 18 cents per diluted share for the three months ended June 30 compared with a profit of eight cents per share a year earlier.

Revenue slipped to $14.2-million compared with $15.1-million a year ago.

Story continues below advertisement

The result came as Dye & Durham says it cut $4.1-million in costs compared with its third quarter through permanent and temporary measures in response to the COVID-19 pandemic.

Dye & Durham completed its initial public offering and began trading on the Toronto Stock Exchange on July 17.

It raised $172.5-million in the offering and over-allotment option.

-The Canadian Press

**

Knight Therapeutics Inc. (GUD-T) and TherapeuticsMD, Inc. (TXMD-Q) announced the approval of Bijuva capsules by Health Canada.

Story continues below advertisement

Bijuva helps with menopause symptoms, such as hot flashes and night sweats, the company said.

Knight signed a license agreement with TherapeuticsMD in July 2018 for the exclusive Canadian commercialization rights to Bujuva. The agreement sees Knight pay TherapeuticsMD a milestone fee for the regulatory approval in Canada of Bijuva, as well as sales milestone fees and royalties.

**

Fiera Capital Corp. (FSZ-T) announced the appointment of Anik Lanthier as president of its public markets division, effective Oct. 13.

“Anik will be responsible for all of Fiera Capital’s public markets activities globally which group the firm’s equity, fixed income, liquid alternatives and multi-asset class solutions offering,” the company stated.

Her most recent role was as senior vice-president and global head of capital markets at PSP Investments.

Story continues below advertisement

**

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies